Endoscopic Ultrasound (EUS) - What Is It? Why Is It Done? How Can Ayurvedic Herbs Help?

ABSTRACT

Endoscopic Ultrasound (EUS) is an advanced diagnostic and minimally invasive imaging technique that combines endoscopy and ultrasonography to obtain detailed images of the digestive tract and surrounding organs. It plays a crucial role in evaluating gastrointestinal diseases, pancreatic disorders, and certain cancers by providing high-resolution visualisation beyond the capabilities of conventional imaging methods. EUS allows physicians not only to examine internal structures but also to obtain tissue samples through guided procedures. The technique enhances diagnostic accuracy, assists in disease staging, and supports therapeutic interventions. Due to its precision and safety, EUS has become an essential tool in modern gastroenterology and oncology. Its integration with fine-needle aspiration has further expanded its clinical applications. The method contributes significantly to early diagnosis and personalised treatment planning. This article discusses the scientific basis, procedure, interpretation, applications, advantages, and Ayurvedic insights related to Endoscopic Ultrasound.

INTRODUCTION

Endoscopic Ultrasound (EUS) represents a sophisticated leap in medical diagnostics, merging the visual capabilities of endoscopy with the deep-tissue imaging of ultrasound. Traditional diagnostic tools, such as abdominal ultrasound, CT scans, and MRI, provide valuable information but may sometimes lack sufficient resolution for detecting small lesions or assessing deeper gastrointestinal layers. Endoscopic Ultrasound (EUS) bridges this gap by combining a flexible endoscope with an ultrasound probe, allowing close-proximity imaging of organs. EUS is particularly useful for evaluating structures located near the gastrointestinal tract, including the pancreas, bile ducts, oesophagus, stomach, and rectum. By placing the ultrasound transducer directly inside the body through the digestive tract, the technique produces highly detailed images. This capability makes EUS indispensable for diagnosing tumours, cysts, inflammatory conditions, and structural abnormalities while guiding minimally invasive interventions.

SCIENTIFIC PRINCIPLE BEHIND THE TEST

The core of EUS lies in High-Frequency Sound Wave Transduction.

• Piezoelectric Effect: The tip of the endoscope contains a piezoelectric crystal. When an electric current is applied, the crystal vibrates, emitting high-frequency sound waves (usually between 5 MHz and 20 MHz).
• Acoustic Impedance: These sound waves travel through the body's tissues. When they hit a boundary between different tissue densities (like the wall of the stomach versus a fluid-filled cyst), some waves bounce back as echoes.
• Image Reconstruction: The transducer captures these returning echoes. Because higher frequencies provide better resolution but shallower penetration, EUS is optimised for "close-up" work.
• Doppler Shift: Many EUS machines utilise the Doppler principle to detect blood flow, allowing the physician to distinguish between a solid tumour and a blood vessel before performing a biopsy.

KEY COMPONENTS OF THE TEST

An EUS setup is a high-tech assembly of several critical parts:

• The Echoendoscope: A specialised, flexible tube equipped with a light source, a lens, and an ultrasound transducer at the distal tip.
• The Processor: A computer system that simultaneously displays the high-definition video feed (endoscopy) and the sonographic cross-section (ultrasound).
• FNA/FNB Needles: Fine-needle aspiration (FNA) or biopsy (FNB) tools that can be passed through a working channel in the scope to collect tissue samples under real-time ultrasound guidance.
• Coupling Medium: To ensure the sound waves travel efficiently into the tissue, a small balloon at the tip of the scope is often inflated with water, or water is infused into the organ cavity to eliminate air pockets.

WHAT IS THE PROCEDURE?

The procedure is typically performed in an outpatient setting and follows these primary stages:

• Preparation: Patients must fast for at least 6 to 8 hours to ensure the upper GI tract is clear. If the EUS is being performed on the lower tract (rectal EUS), a laxative or enema is required.
• Sedation and Insertion: To ensure comfort, "conscious sedation" or general anaesthesia is administered. The physician gently inserts the echoendoscope through the mouth (or anus) and advances it to the area of interest.
• Imaging and Intervention: Once the scope is positioned, the ultrasound is activated. The physician moves the scope precisely to visualise the layers of the GI wall or neighbouring organs. If a suspicious mass is found, a thin needle is passed through the scope and into the mass—a process called EUS-FNA. This allows for "real-time" sampling of cells without an external incision.

INTERPRETATION OF THE TEST

Interpreting an EUS requires a specialised gastroenterologist or radiologist. The focus is on the five distinct layers of the GI wall:

• Mucosa (Hyperechoic/White)
• Deep Mucosa (Hypoechoic/Dark)
• Submucosa (Hyperechoic)
• Muscularis Propria (Hypoechoic)
• Serosa/Adventitia (Hyperechoic)

Disruption of these layers often indicates the depth of a tumour's invasion (T-staging). In the pancreas, the doctor looks for changes in "echotexture"—solid masses appear darker (hypoechoic) than healthy tissue, while cysts appear black (anechoic) because they contain fluid.

HEALTH ISSUES WHERE EUS IS ADVISED

EUS is a versatile tool used for both diagnosis and therapy. It is commonly advised in Pancreatic cancer and chronic pancreatitis. Other than pancreas, it is commonly used to diagnose following health issues:

• Cancer Staging: Determining the extent of oesophageal, gastric, pancreatic, and rectal cancers to decide if surgery is feasible.
• Subepithelial Lesions: Investigating "bumps" found during standard endoscopy to see if they are benign fat (lipomas) or potentially malignant stromal tumours (GISTs).
• Biliary Issues: Finding tiny gallstones or "sludge" in the bile duct that cause unexplained pain.
• Therapeutic Drainage: Using ultrasound guidance to drain pseudocysts in the pancreas or to perform a celiac plexus block for chronic pain management.

FACTORS AFFECTING THE RESULTS OF EUS

While highly accurate, several factors can influence the quality of the findings:

• Operator Expertise: EUS is highly "user-dependent." The skill of the endoscopist in manoeuvring the scope and interpreting the subtle grey-scale images is paramount.
• Air Interference: Ultrasound waves cannot travel through air. If the bowel is overly distended with gas, the view can be blocked.
• Previous Surgery: Scar tissue or altered anatomy from prior gastric or oesophageal surgeries can make scope placement difficult.
• Anatomical Variations: Obesity or severe scoliosis can sometimes shift internal organs into positions that are difficult to reach via the GI tract.

ADVANTAGES OF THE TEST

• Higher Resolution: It provides much higher resolution images of the GI wall and pancreas than MRI or CT.
• Real-time Biopsy: Unlike other imaging, EUS allows for an immediate biopsy of deep structures with a lower risk than percutaneous (through the skin) biopsies.
• Safety: There is no exposure to ionising radiation, unlike CT scans or X-rays.
• Minimally Invasive: It provides surgical-level information without the need for an incision or a long recovery period.

AYURVEDA INSIGHT

Ayurveda emphasises the importance of understanding the Srotas (channels) and Ashayas (cavities or seats of organs). In Ayurvedic diagnostics (Rogi pariksha), physicians traditionally use palpation (Sparshana) and listening to internal sounds (Shravana) to detect imbalances. EUS can be viewed as a modern extension of these senses—a "divine eye" (Divya Chakshu) that allows the practitioner to see Ama (toxins/blockages) or Granthi (tumours/growths) that were previously hidden. Using EUS results, an Ayurvedic practitioner can more accurately suggest Shodhana (cleansing) or Shamana (balancing) therapies by knowing exactly where the physical obstruction lies.

HERBS THAT ARE USED IN PANCREATIC CANCER

Haridra (Curcuma longa)

In Ayurveda, Haridra is classified as a powerful Kaphahara (balances Kapha dosha) and Vishaghna (Anti-poisoning) herb that purifies blood and reduces chronic inflammation linked with tumour development. It supports liver and digestive function, thereby improving systemic detoxification processes important in pancreatic disorders. Haridra is also considered beneficial for maintaining healthy tissue regeneration and immunity. Modern research identifies curcumin as its principal active compound with extensive anticancer potential. Curcumin modulates multiple molecular targets, including inflammatory cytokines, growth factors, and apoptotic pathways. Studies show it may inhibit pancreatic cancer cell growth, reduce oxidative stress, and enhance sensitivity to therapeutic interventions.

Guggul (Commiphora wightii)

In Ayurveda, Guggul is described as a potent Lekhaniya (Scraping) and Shothahara (anti-inflammatory) herb that helps dissolve abnormal tissue accumulation and clears obstructed channels (Srotorodha). Pancreatic disorders are often associated with aggravated Kapha and impaired digestive fire (Mandagni), where Guggul supports metabolic correction and detoxification. It enhances circulation and assists in removing deep-seated toxins contributing to disease progression. From a modern perspective, the resin contains guggulsterones, which regulate inflammatory signalling pathways such as NF-κB involved in tumour growth. These compounds demonstrate anti-proliferative and apoptosis-inducing properties in experimental cancer studies. Guggul also influences lipid metabolism and cellular signalling, which may help reduce tumour-supportive inflammatory environments.

Kanchnaar (Bauhinia variegata)

Kanchnaar is traditionally used in Ayurveda for managing Granthi and Arbuda (abnormal growths and tumours), conditions resembling abnormal glandular enlargement and tumour formation. It balances Kapha dosha and supports lymphatic cleansing, which is considered essential in preventing pathological tissue overgrowth. Ayurvedic texts emphasise its role in breaking stagnation and improving tissue metabolism (Dhatu Agni). Modern research identifies flavonoids such as quercetin and kaempferol as key bioactive constituents. These compounds exhibit antioxidant activity and help regulate oxidative stress, a major factor in pancreatic carcinogenesis. Studies suggest they may interfere with abnormal cell signalling pathways and support controlled cellular turnover.

Shallaki (Boswellia serrata)

In Ayurveda, Shallaki is valued for reducing Shotha (inflammation) and supporting tissue healing. Chronic inflammation is considered a root factor in serious abdominal disorders, and Shallaki helps restore structural harmony in affected tissues. It improves circulation and relieves discomfort associated with deep-seated inflammatory conditions. Modern science attributes its therapeutic potential to boswellic acids, particularly AKBA (Acetyl-11-keto-β-boswellic acid). These compounds inhibit inflammatory enzymes and suppress pathways linked with tumour angiogenesis and metastasis. Research indicates boswellic acids may slow cancer cell proliferation and reduce inflammatory mediators within pancreatic tissues.

Fenugreek (Trigonella foenum-graecum)

Fenugreek is recognised in Ayurveda for enhancing digestion (Deepana-Pachana) and correcting metabolic imbalance, which is crucial in disorders involving weakened pancreatic function. It supports glucose metabolism and nourishes body tissues while preventing excessive Kapha accumulation. Ayurveda associates proper pancreatic health with balanced digestion and nutrient assimilation, areas where Fenugreek plays a supportive role. Modern investigations highlight compounds such as diosgenin and trigonelline, which possess anti-cancer and antioxidant activities. Diosgenin has been shown to influence apoptosis pathways and inhibit the proliferation of certain cancer cell lines. Additionally, Fenugreek's fiber and polyphenols contribute to improved metabolic regulation, indirectly supporting pancreatic health.

CONCLUSION

Endoscopic Ultrasound is a masterclass in medical synergy. By taking ultrasound deep inside the body, it has transformed the way we diagnose and treat complex internal diseases. Whether it is providing the definitive stage of a cancer diagnosis or guiding a needle to relieve chronic pain, EUS offers a level of precision that was once unimaginable. As technology advances, with the integration of Artificial Intelligence for image analysis and elastography to measure tissue stiffness, EUS will continue to be an indispensable sentinel in the field of modern gastroenterology.

CA 19-9 Tumour Marker - What Is It? Why Is It Done? How Can Ayurvedic Herbs Help?

ABSTRACT

Carbohydrate Antigen 19-9 (CA 19-9) is a widely used tumour marker primarily associated with pancreatic and certain gastrointestinal malignancies. It is a glycoprotein antigen measured in the blood and serves as an important biomarker for monitoring disease progression, therapeutic response, and recurrence, rather than as a standalone diagnostic tool. Elevated CA 19-9 levels are commonly observed in pancreatic cancer, biliary tract cancers, and some colorectal and gastric cancers, but they may also rise in benign conditions such as pancreatitis and liver diseases. This article provides a detailed overview of the CA 19-9 tumour marker, including its scientific basis, procedure, interpretation, clinical applications, influencing factors, and an Ayurvedic perspective on related disorders.

INTRODUCTION

In the landscape of oncology, biomarkers act as essential signalling molecules that provide a window into the biological behaviour of a tumour. CA 19-9 is a modified blood group antigen, specifically a sialylated Lewis (a) antigen. It was discovered in the late 1970s, and it has become the "gold standard" serum marker for pancreatic cancer. However, its clinical utility is a nuanced subject. While high levels are often synonymous with malignancy, CA 19-9 is not "cancer-specific"; it can be elevated in several non-malignant conditions involving the liver and bile ducts.

SCIENTIFIC PRINCIPLE BEHIND THE CA 19-9 TUMOUR MARKER

At a molecular level, CA 19-9 is a carbohydrate structure found on the surface of certain cancer cells. It is typically shed into the bloodstream, where it can be measured via a venous blood draw. The scientific foundation of the CA 19-9 test relies on Immunometric Assays, most commonly the Enzyme-Linked Immunosorbent Assay (ELISA) or Chemiluminescent Immunoassay (CLIA).

THE MECHANISM

• Antibody Capture: The patient's serum is mixed with specific monoclonal antibodies (known as 1116-NS-19-9) that "seek out" and bind to the CA 19-9 carbohydrate chains.
• Signal Generation: A second antibody, labelled with an enzyme or a fluorescent marker, binds to the CA 19-9/antibody complex.
• Quantification: The intensity of the signal (light or colour change) is directly proportional to the concentration of the antigen in the blood.

KEY COMPONENTS OF CA 19-9 TUMOUR MARKER

The structure and efficacy of CA 19-9 are dictated by several biological components:

• Sialylated Lewis Antigen: The core chemical structure. It is essentially a sugar chain attached to proteins (glycoproteins) or lipids (glycolipids).
• The Lewis Gene: A patient's genetic makeup determines if they can even produce CA 19-9. Roughly 5% to 10% of the population are "Lewis negative" ($Le^{a-b-}$), meaning they lack the enzyme needed to synthesise CA 19-9. In these individuals, the marker will remain undetectable even in the presence of an advanced tumour.
• Excretion Pathway: CA 19-9 is primarily excreted through the bile. Consequently, any blockage in the bile ducts (cholestasis) can lead to a backup of this marker into the blood, causing "false positive" elevations.

WHAT IS THE PROCEDURE?

The procedure for a CA 19-9 test is straightforward and minimally invasive, similar to a routine cholesterol check.

• Preparation: No specific fasting is usually required, though patients should inform their doctor about any supplements (like Biotin) that might interfere with lab assays.
• Collection: A healthcare professional performs a venipuncture, usually in the arm, to collect a small vial of blood.
• Processing: The blood is centrifuged to separate the serum. The serum is then analysed using the immunoassay techniques.
• Turnaround Time: Results are typically available within 24 to 48 hours.

INTERPRETATION OF THE TEST

Interpreting CA 19-9 requires a "big picture" approach. The standard reference range is generally 0–37 U/mL (Units per millilitre).

• Normal Levels (<37 U/mL): Generally suggests the absence of a CA 19-9 producing tumour, though it does not rule out cancer in Lewis-negative individuals.
• Moderately Elevated Levels (37 to 100 U/mL): These levels are often seen in benign conditions like gallstones, pancreatitis, or liver cirrhosis.
• Significantly High Levels (>1,000 U/mL): Highly suggestive of malignancy, particularly pancreatic or biliary tract cancers. In known cancer patients, a rising trend usually indicates disease progression.
• Post-Treatment Decline: A significant drop in levels following surgery or chemotherapy is a strong indicator of successful treatment.

HEALTH ISSUES WHERE CA 19-9 TUMOUR MARKER IS ADVISED

The CA 19-9 test is commonly recommended in the following conditions:

• Symptomatic Pancreatic Issues: Patients presenting with jaundice, weight loss, and abdominal pain.
• Monitoring Pancreatic Cancer: To assess if chemotherapy or radiation is shrinking the tumour.
• Post-Surgical Surveillance: To check for the recurrence of cancer after it has been removed.
• Differential Diagnosis: Helping distinguish between pancreatic cancer and other conditions like chronic pancreatitis.
• Biliary Tract Disorders: Including cholangiocarcinoma (bile duct cancer) and gallbladder cancer.
• Colorectal and Gastric Cancers: In selected cases for disease monitoring.

It is especially valuable in patients already diagnosed with cancer to assess tumour burden and guide management decisions.

FACTORS AFFECTING THE RESULTS OF THE CA 19-9 TUMOUR MARKER

Several factors may influence CA 19-9 levels:

• Biliary Obstruction: Jaundice (high bilirubin) is the most common cause of false positives. When bile can't flow, CA 19-9 levels skyrocket.
• Inflammatory Diseases: Acute pancreatitis, diverticulitis, and inflammatory bowel disease (IBD) can cause mild elevations.
• Liver Disease: Cirrhosis or hepatitis interferes with the body's ability to clear the marker.
• Genetic Factors: As noted, Lewis-negative individuals will provide "false negatives" even if a tumour is present.
• Technical Variations: Differences in laboratory methods may slightly alter reference ranges.
  

Therefore, abnormal results must be interpreted cautiously and confirmed with imaging and additional clinical evaluation.

ADVANTAGES OF THE TEST

• Prognostic Value: Initial levels at the time of diagnosis can help predict the severity of the disease.
• Early Detection of Recurrence: Often, CA 19-9 levels will begin to rise months before a tumour is visible on a CT or MRI scan.
• Cost-Effective Monitoring: It is a relatively inexpensive way to track treatment efficacy compared to frequent high-resolution imaging.
• Ease of Access: Because it only requires a blood sample, it can be performed frequently without physical strain on the patient.
• Non-invasive: Requires only a blood sample.

AYURVEDA INSIGHT

In the context of Ayurveda, the presence of a tumour or "Granthi/Arbuda" is viewed as an imbalance of the Tridoshas (Vata, Pitta, and Kapha), often involving the deep tissues (Dhatus). In Ayurveda, there is no direct correlation to a carbohydrate antigen, but the elevation of such markers can be correlated with the following conditions:

• Agni Mandya (Weak Digestive Fire): Chronic low Agni leads to the formation of Ama (metabolic toxins). These toxins can manifest as abnormal cellular growths.
• Srotorodha (Channel Blockage): The elevation of CA 19-9 in cases of jaundice aligns with the Ayurvedic concept of Koshthashrita Kamala (Obstructive Jaundice), where the flow of Pitta (bile) is obstructed.

Ayurvedic management focuses on Deepana-Pachana (strengthening digestion and clearing toxins) and Rasayana (rejuvenation) therapies to support the body's immune system alongside conventional treatments.

AYURVEDIC HERBS USED FOR PANCREATIC CANCER

Pancreatic cancer is considered a serious and progressive disorder that, in Ayurveda, can be correlated with conditions involving Arbuda (malignant growth) and severe imbalance of the three Doshas, along with impaired Agni (digestive and metabolic fire). The disease is often associated with Ama (Toxins) accumulation, tissue depletion (Dhatu kshaya), and obstruction of bodily channels (Srotorodha), leading to weakness and systemic deterioration. Ayurvedic management focuses on restoring doshic balance, improving digestion and metabolism, detoxifying the body, reducing inflammation, and supporting immunity (Ojas). Here are some common herbs that are used in this condition:

Haridra (Curcuma longa)

In Ayurveda, Haridra (Turmeric) is widely used for reducing inflammation, purifying blood, and removing Ama (metabolic toxins). Pancreatic disorders are often linked with impaired Agni (Digestive Fire) and inflammatory accumulation, where Haridra helps by improving digestion and supporting tissue metabolism. From a modern scientific perspective, the major active compound curcumin exhibits strong anti-inflammatory, antioxidant, and anti-proliferative properties. Curcumin modulates molecular pathways such as NF-κB, STAT3, and COX-2 involved in pancreatic tumour growth and chronic inflammation. It helps inhibit cancer cell proliferation, induce apoptosis, and reduce tumour angiogenesis, supporting pancreatic health at the molecular level.

Guggul (Commiphora wightii)

In Ayurvedic texts, Guggul (Indian Bdellium) is considered Lekhaniya (scraping) and Shothahara (anti-inflammatory), helping dissolve abnormal tissue growths and improve channel circulation (Srotoshodhana). It is traditionally used in disorders involving glandular swelling and metabolic stagnation associated with tumour development. Modern research identifies guggulsterones (E- and Z-guggulsterone) as key bioactive compounds responsible for their therapeutic effects. These compounds regulate nuclear receptors and inhibit inflammatory signalling pathways linked with cancer progression. Guggulsterones have shown potential to suppress proliferation and promote apoptosis in pancreatic cancer cells while supporting metabolic balance.

Kanchnaar (Bauhinia variegata)

Kanchnaar (Mountain Ebony) is highly valued in Ayurveda for managing Granthi and Arbuda (abnormal growths and tumours). It balances Kapha dosha and supports the reduction of glandular enlargement by improving lymphatic and metabolic circulation. Modern pharmacological studies reveal the presence of flavonoids such as kaempferol and quercetin, which possess antioxidant and anticancer activities. These phytochemicals help reduce oxidative stress, inhibit abnormal cell proliferation, and regulate inflammatory cytokines involved in pancreatic cancer progression.

Ashwagandha (Withania somnifera)

In Ayurveda, Ashwagandha (Withania somnifera) is classified as a powerful Rasayana that enhances vitality, strengthens immunity (Ojas), and supports recovery in chronic debilitating diseases. Pancreatic cancer often leads to weakness and tissue depletion (Dhatu kshaya), where Ashwagandha helps restore strength and resilience. Modern science attributes its anticancer potential mainly to withanolides, especially withaferin A, which shows cytotoxic activity against pancreatic cancer cells. These compounds induce apoptosis, inhibit tumour proliferation, and suppress angiogenesis while modulating oxidative stress pathways. Ashwagandha also acts as an adaptogen, helping improve overall quality of life.

Shallaki (Boswellia serrata)

Shallaki (Boswellia serrata) is described in Ayurveda as an excellent Shothahara (anti-inflammatory) herb that balances Pitta and Kapha while supporting tissue healing and reducing chronic swelling. Since persistent inflammation contributes to Arbuda (abnormal growths and tumours) formation, Shallaki helps regulate inflammatory processes and maintain tissue integrity. The primary active constituents are boswellic acids, particularly AKBA (Acetyl-11-keto-β-boswellic acid). These compounds inhibit the 5-lipoxygenase (5-LOX) pathway, reducing inflammatory mediators associated with cancer progression. Research suggests boswellic acids may suppress tumour cell growth, reduce metastasis potential, and promote apoptosis in pancreatic cancer models.

CONCLUSION

The CA 19-9 tumour marker is a sophisticated tool in the oncologist's arsenal, but it is not a standalone diagnostic "silver bullet." Its true power lies in serial monitoring, watching how the numbers change over time in response to therapy. While it provides critical insights into pancreatic and biliary health, clinicians must always interpret these values in the context of the patient's genetic background, liver function, and imaging results. By combining modern laboratory precision with a holistic understanding of the body's internal environment, we can better navigate the complexities of cancer care.